<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00204243</url>
  </required_header>
  <id_info>
    <org_study_id>Project B: 160115</org_study_id>
    <nct_id>NCT00204243</nct_id>
    <nct_alias>NCT00520793</nct_alias>
  </id_info>
  <brief_title>Naltrexone Implants vs. MMT Among Inmates in the Norwegian Correctional Services</brief_title>
  <official_title>Naltrexone Implants Compared to Methadone Maintenance Treatment (MMT) Among Inmates About to be Released From Prison - a Randomized Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Oslo</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>The Research Council of Norway</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Oslo</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this clinical trial is to study the efficacy and safety of naltrexone implants
      as a relapse prevention for opiate addicted inmates about to be released from prison. The
      experimental group is compared with a control group that commences methadone maintenance
      treatment before release.

      The hypothesises are that quality of life and criminal behaviour improve significantly in
      both groups compared to the month before incarceration. The experimental group is going to
      have significant less days with opioid use compared to the MMT group.

      We hypothesize furthermore that the implants can prevent death related to opiate overdose up
      to 6 months after commenced treatment.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The probability of quick relapse to criminal activity and substance abuse after prison
      release is high among incarcerated opiate addicts.

      We attempt to prevent relapse to opiate abuse by two different means:

      Methadone Maintenance Treatment (MMT) versus Naltrexone implants, randomly allocated to two
      groups by sealed envelopes.

      All participants may choose in which group to continue after 6 (and again after 12) months,
      when the implants supposedly stop releasing naltrexone.

      The total treatment period is 18 months, continuation with MMT is optional after study
      termination.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2005</start_date>
  <completion_date type="Actual">December 2008</completion_date>
  <primary_completion_date type="Actual">February 2008</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Drug use: self reported, urin / hair analysis</measure>
    <time_frame>6, 12 and 18 months</time_frame>
    <description>Use of heroin and other illicit drugs, self reported and in hair analyses</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Distress / depression: BDI and Hopkins SCL-25</measure>
    <time_frame>6, 12 and 18 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life, temporary satisfaction with life scale &amp; self report as of ASI</measure>
    <time_frame>6, 12 and 18 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">46</enrollment>
  <condition>Opiate Addiction</condition>
  <arm_group>
    <arm_group_label>Naltrexone implant</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Naltrexone implant (GoMedical Inc. 6 months implant)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Methadone</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Methadone Maintenance Treatment</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Naltrexone</intervention_name>
    <description>surgically implanted naltrexone releasing during 5 to 6 months</description>
    <arm_group_label>Naltrexone implant</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Methadone</intervention_name>
    <description>Methadone maintenance treatment, flexible high dose (80 to 120 mg / Day)</description>
    <arm_group_label>Methadone</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  opiate addiction

          -  living in greater Oslo area

        Exclusion Criteria:

          -  psychosis / major depression, currently not treated

          -  pregnancy

          -  liver enzymes: ASAT or ALAT &gt; threefold above upper boundary
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Philipp Lobmaier, cand. med.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Unit for Addiction Medicine</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Helge Waal, professor</last_name>
    <role>Study Director</role>
    <affiliation>Unit for Addiction Medicine, University of Oslo</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Michael Abdelnoor, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Ullevål University Hospital, Centre for clinical research</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jørg Mørland, professor</last_name>
    <role>Study Chair</role>
    <affiliation>Division of Forensic Toxicology and Drug Abuse</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Asbjørg S Christophersen, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Division of Forensic Toxicology and Drug Abuse</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Unit for Addiction Medicine</name>
      <address>
        <city>Oslo</city>
        <zip>0407</zip>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Norway</country>
  </location_countries>
  <reference>
    <citation>Hulse GK, Arnold-Reed DE, O'Neil G, Chan CT, Hansson RC. Achieving long-term continuous blood naltrexone and 6-beta-naltrexol coverage following sequential naltrexone implants. Addict Biol. 2004 Mar;9(1):67-72.</citation>
    <PMID>15203441</PMID>
  </reference>
  <reference>
    <citation>Hulse GK, Arnold-Reed DE, O'Neil G, Chan CT, Hansson R, O'Neil P. Blood naltrexone and 6-beta-naltrexol levels following naltrexone implant: comparing two naltrexone implants. Addict Biol. 2004 Mar;9(1):59-65.</citation>
    <PMID>15203440</PMID>
  </reference>
  <reference>
    <citation>Hulse GK, Tait RJ, Comer SD, Sullivan MA, Jacobs IG, Arnold-Reed D. Reducing hospital presentations for opioid overdose in patients treated with sustained release naltrexone implants. Drug Alcohol Depend. 2005 Sep 1;79(3):351-7.</citation>
    <PMID>15899557</PMID>
  </reference>
  <reference>
    <citation>Olsen L, Christophersen AS, Frogopsahl G, Waal H, Mørland J. Plasma concentrations during naltrexone implant treatment of opiate-dependent patients. Br J Clin Pharmacol. 2004 Aug;58(2):219-22.</citation>
    <PMID>15255807</PMID>
  </reference>
  <reference>
    <citation>Bachs L, Waal H. [Naltrexone in the treatment of addiction]. Tidsskr Nor Laegeforen. 2003 Jun 12;123(12):1665-7. Norwegian.</citation>
    <PMID>12821984</PMID>
  </reference>
  <reference>
    <citation>Waal H, Christophersen AS, Frogopsahl G, Olsen LH, Mørland J. [Naltrexone implants--a pilot project]. Tidsskr Nor Laegeforen. 2003 Jun 12;123(12):1660-1. Norwegian.</citation>
    <PMID>12821982</PMID>
  </reference>
  <verification_date>May 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 13, 2005</study_first_submitted>
  <study_first_submitted_qc>September 16, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 20, 2005</study_first_posted>
  <last_update_submitted>May 18, 2011</last_update_submitted>
  <last_update_submitted_qc>May 18, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 19, 2011</last_update_posted>
  <responsible_party>
    <name_title>Philipp Lobmaier</name_title>
    <organization>University of Oslo</organization>
  </responsible_party>
  <keyword>naltrexone implant</keyword>
  <keyword>methadone</keyword>
  <keyword>inmates</keyword>
  <keyword>randomized controlled trial</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Opioid-Related Disorders</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Naltrexone</mesh_term>
    <mesh_term>Methadone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

